How to de-risk drug development from the earliest stages

How do biotech innovators prioritize decision-making from pre-clinical phases to set up clinical development for the best chance of commercial success? This panel discussion explores the business-critical actions at key milestones that ultimately determine a product’s value story.

Delivered at BIO International in San Diego on June 6, this session covers a wide range of perspectives – from biotech sponsors, investors and market access leaders – focused on the importance of prioritizing and focusing on the most critical aspects in early drug development, given often limited resources. Watch the panel discussion on-demand now, to find out more about the importance of flexible clinical development strategies, engaging with regulators early, the need to continuously update TPPs based on evolving competitive landscapes and the potential of AI tools in drug development. 

Return to Insights Center